Mr. Michael McFadden reports

ALPHA COGNITION ANNOUNCES AMENDED TERMS OF PRIVATE PLACEMENT AND CONTINUATION OF THE OFFERING

Alpha Cognition Inc. has amended the terms of its previously announced private placement offering of up to $6.5-million (U.S.) of units at a price of 22 cents per unit. Each unit will consist of one common share and one warrant. Each warrant will entitle the holder to purchase an additional common share of the company at a price of 31 U.S. cents per common share for a period of three years from the closing date.

Pursuant to previous closings of the offering, the company raised approximately $2.7-million (U.S.) through the issuance of an aggregate of 12,301,791 units composed of one common share and one-half of one common share purchase warrant. The previous closing warrants are exercisable into common shares at a price of 31 U.S. cents per common share for three years following the date of issuance. The company is continuing the offering with the amended warrant terms for up to an additional $3.8-million (U.S.).

All securities issued pursuant to the offering will be subject to a four-month statutory hold period under Canadian securities laws and restrictions under U.S. securities laws, which generally restrict resales for a period of 12 months. The company expects to use the net proceeds from the offering for research and development, general and administrative matters, and working capital.

About Alpha Cognition Inc.

Alpha Cognition is a clinical-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive impairment with mild traumatic brain injury, for which there are currently no approved treatment options.

Alpha-1062 is a patented new chemical entity being developed as a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. Alpha-1062's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the Alpha-7 subtype, which is known to have a positive effect on cognition. Alpha-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and as an intranasal formulation for cognitive impairment with mTBI.

We seek Safe Harbor.